Hsiu-Chiung Yang,
HC Yang,
Wu-Kuang Yeh,
J. R. McCarthy
e.a.
John Wiley & Sons
e druk, 2014
9780470286265
Enzyme Technologies – Pluripotent Players Discovering Therapeutic Agents
Pluripotent Players in Discovering Therapeutic Agent
Specificaties
Gebonden, 356 blz.
|
Engels
John Wiley & Sons |
e druk, 2014
ISBN13: 9780470286265
Rubricering
Onderdeel van serie
Chemical Biology of Enzymes for Biotechnology and Pharmaceutical Applications
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
Highlighting the critical importance of enzymes in pharmaceutical and biotechnology research,
Enzyme Technologies presents thorough discussions on chemical biology of enzymes, redesigning binding and catalytic specificities of enzymes, and applications of enzymes to biotechnology research in the post–genomic era. This timely review presents researchers, students, and faculty with expert reviews of recent progress in comprehending molecular mechanisms of biosynthetic and biocatalytic processes as well as how to utilize that knowledge for practical applications.
Specificaties
Inhoudsopgave
<p>Contributors vii</p>
<p>Preface ix</p>
<p>Part A —Enzymes essential workhorses in pharmaceutical research 1</p>
<p>1 Assay Technologies for Proteases 3<br /> Anuradha Roy, Gerald H. Lushington, James McGee, and Rathnam Chaguturu</p>
<p>2 Discovery and Development of Isozyme–Selective Inhibitors Involved in Lipid Metabolism 55<br /> Taichi Ohshiro and Hiroshi Tomoda</p>
<p>3 Covalent Enzyme Inhibition in Drug Discovery and Development 81<br /> Shujaath Mehdi</p>
<p>4 Preclinomics: Enzyme Assays and Rodent Models for Metabolic diseases 131<br /> Wu–Kuang Yeh and Richard G. Peterson</p>
<p>Part B —Enzymes indispensable tools for improving druggability 163</p>
<p>5 Enzymes and Targeted Activation of Prodrugs 165<br /> Yanhui Yang, Yu Chen, Herve Aloysius, Daigo Inoyama, and Longqin Hu</p>
<p>6 Evolution of an Orally Active Prodrug of Gemcitabine 237<br /> James R. McCarthy</p>
<p>7 Enzymatically Activated Phosphate and Phosphonate Prodrugs 253<br /> Ivan S. Krylov and Charles E. McKenna</p>
<p>Part C E nzymes powerful weapons for correcting Nature s errors 301</p>
<p>8 Treatment Options for Mucopolysaccharidosis Type II (Hunter s Syndrome) 303<br /> Michael Beck</p>
<p>9 Enzyme Replacement Therapy for Fabry Disease 321<br /> Ley Nadine Lacbawan, Wei Zheng, and Ozlem Goker–Alpan</p>
<p>10 Methods and Principles of Pancreatic Function Tests 335<br /> Henrike von Schassen, Jutta Keller, and Peter Layer</p>
<p>Index 341</p>
<p>Preface ix</p>
<p>Part A —Enzymes essential workhorses in pharmaceutical research 1</p>
<p>1 Assay Technologies for Proteases 3<br /> Anuradha Roy, Gerald H. Lushington, James McGee, and Rathnam Chaguturu</p>
<p>2 Discovery and Development of Isozyme–Selective Inhibitors Involved in Lipid Metabolism 55<br /> Taichi Ohshiro and Hiroshi Tomoda</p>
<p>3 Covalent Enzyme Inhibition in Drug Discovery and Development 81<br /> Shujaath Mehdi</p>
<p>4 Preclinomics: Enzyme Assays and Rodent Models for Metabolic diseases 131<br /> Wu–Kuang Yeh and Richard G. Peterson</p>
<p>Part B —Enzymes indispensable tools for improving druggability 163</p>
<p>5 Enzymes and Targeted Activation of Prodrugs 165<br /> Yanhui Yang, Yu Chen, Herve Aloysius, Daigo Inoyama, and Longqin Hu</p>
<p>6 Evolution of an Orally Active Prodrug of Gemcitabine 237<br /> James R. McCarthy</p>
<p>7 Enzymatically Activated Phosphate and Phosphonate Prodrugs 253<br /> Ivan S. Krylov and Charles E. McKenna</p>
<p>Part C E nzymes powerful weapons for correcting Nature s errors 301</p>
<p>8 Treatment Options for Mucopolysaccharidosis Type II (Hunter s Syndrome) 303<br /> Michael Beck</p>
<p>9 Enzyme Replacement Therapy for Fabry Disease 321<br /> Ley Nadine Lacbawan, Wei Zheng, and Ozlem Goker–Alpan</p>
<p>10 Methods and Principles of Pancreatic Function Tests 335<br /> Henrike von Schassen, Jutta Keller, and Peter Layer</p>
<p>Index 341</p>